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TO THE EDITOR
Psoriasis is characterized by keratino-
cyte proliferation, inflammation, and
mast cell activation (Schon and
Boehncke, 2005). It is also triggered or
exacerbated by acute stress (Katsarou-
Katsari et al., 1999; Saraceno et al.,
2006); however, this mechanism
remains poorly understood. Stress typi-
cally results in release of corticotropin-
releasing hormone (CRH) from the
hypothalamus and regulates the hy-
pothalamic–pituitary–adrenal (HPA)
axis (Chrousos, 1995) through activa-
tion of CRH receptor-1 (CRH-R1),
leading to immunosuppression. CRH is
also found peripherally (Chrousos,
1995) and has pro-inflammatory effects
through mast cell activation (Theohar-
ides et al., 1998). CRH and CRH-R gene
expression has been documented in
rodent and human skin (Slominski
et al., 2001). In fact, it has been
proposed that skin has the equivalent
of the HPA axis (Slominski et al., 2000).
In mice, CRH is released from nerve
endings (Slominski et al., 2001),
whereas in humans it is synthesized
by skin cells (Slominski et al., 1998),
immune cells (Karalis et al., 1997), and
human mast cells (Kempuraj et al.,
2004).
To study the effect of stress and the
role of CRH in psoriasis, we investi-
gated, by quantitative PCR, CRH-R
expression in affected and unaffected
skin of psoriasis patients (n¼13) and
skin from normal controls (n¼ 4), as
well as serum CRH levels from psoriasis
patients (n¼8) and controls (n¼4). The
characteristics of the subjects (Table S1)
were as follows: male mean age
47.477.0 years (n¼ 7); female mean
age 28.075.2 years (n¼ 6); normal
subjects (one male, three female sub-
jects, mean age 40715.2 years). All
skin biopsies requiring two stitches
were collected for diagnostic purposes
(Table S1). The Medical Ethics Commit-
tee of Attikon Hospital HIRB approved
this protocol. All participants gave their
written informed consent according to
the Declaration of Helsinki Principles.
Patients had moderate chronic plaque
psoriasis with psoriasis area and sever-
ity index (PASI) scores 5–16 and had
not received any therapy for psoriasis
(topical or systemic) for the past month.
The PASI score for males was
11.3713.5 and for females was
11.573.7.
Expression of CRH-R1 mRNA was
lowest in affected samples from psoriasis
patients (0.2770.23, n¼ 13, Po0.05),
compared with control patients (Figure
1a). CRH-R1 expression in unaffected
skin from psoriasis patients (0.5370.38)
was not statistically different from that of
affected samples or controls (Figure 1a).
There was no statistically significant
difference in CRH-R2 mRNA expression
among the control samples, those ob-
tained from affected (0.8670.51) and
from unaffected (0.9770.65) psoriatic
skin (Figure 1a).
The serum CRH level (11.527
6.09 pg/ml) was higher (n¼8, Po0.05)
in psoriasis patients than controls
(5.4271.2 pg/ml, n¼ 8). There was no
apparent correlation between the PASI
scores and either CRH-R1 expression or
serum CRH levels.
This study provides early evidence
that affected psoriatic skin has decreased
gene expression of CRH-R1 mRNA than
normal controls. One possible explana-
tion is that overstimulation by increased
levels of local or systemic (serum) CRH
in psoriasis patients, possibly in response
to chronic stress, may lead to CRH-R1
downregulation. In fact, CRH protein
expression was recently reported to be
increased in the affected skin of three
patients with active psoriasis than in one
control; however, this effect was not
quantitated (O’Kane et al., 2006). As
non-affected psoriatic skin apparently
did not overexpress CRH-R, as shown
by our quantitative real-time–PCR data,
there was apparently no mechanism in
place to lead to downregulation. In-
creased CRH-R expression in psoriatic
skin was also mentioned as ‘‘unpub-
lished observations’’ (O’Kane et al.,
2006) and it is, therefore, difficult to
evaluate it. The reduction in CRH-R1
mRNA expression in affected skin of
patients with psoriasis we observed
could be due to the intense inflamma-
tion seen in plaques without any asso-
ciation with serum CRH levels; how-
Abbreviations: CRH, corticotropin-releasing hormone; HPA, hypothalamic–pituitary–adrenal; CRH-R1,
CRH receptor-1; PASI, psoriasis area and severity index
www.jidonline.org 1789
M Tagen et al.
Skin CRH Receptors in Psoriasis
ever, this possibility is not supported by
the literature. In fact, we showed that the
inflammation-related molecules IL-1,
IL-4, and lipopolysaccharide had no
effect on CRH-R1 expression, but in-
creased CRH-R2 expression in human
mast cells (Papadopoulou et al., 2005).
CRH-R1 is expressed in keratinocytes
(Slominski and Wortsman, 2000) and in
a subpopulation of skin mast cells
(Donelan et al., 2006). Normal cultured
human mast cells also express mRNA
and protein for CRH-R1 and CRH-R2
(Cao et al., 2005). Human skin, squa-
mous cell carcinoma, and melanoma
cells also express CRH and CRH-R1
(Slominski et al., 1998, 2001). The lack
of any significant difference between
affected and unaffected or control skin
may either indicate (a) that unaffected
skin represents an early or intermediate
stage, (b) that these areas have different
number of cells expressing CRHR, or (c)
the variability is too large, given the
small number of patients.
Psoriasis is the most common
chronic inflammatory skin disorder
(Schon and Boehncke, 2005). It is
worsened by stress (Katsarou-Katsari
et al., 1999) and is characterized by
aberrant HPA function (Richards et al.,
2005); moreover, neuropeptides appear
to induce skin neurogenic inflammation
(Saraceno et al., 2006). The skin may
have its own equivalent of the HPA axis
(Slominski et al., 2000; Slominski and
Wortsman, 2000) and the role of CRH
in cutaneous inflammatory diseases
was reviewed recently (O’Kane et al.,
2006). Chronic stress and CRH typically
attenuate immune processes, whereas
acute stress enhances antigen-specific,
cell-mediated immunity (Dhabhar and
McEwen, 1999). Stress also exacerbates
contact dermatitis in rats (Kaneko et al.,
2003). Acute stress induces local re-
lease of CRH in the skin (Lytinas et al.,
2003) and increases skin vascular per-
meability (Singh et al., 1999), an effect
mimicked by intradermal CRH and
absent in mast cell-deficient mice
(Theoharides et al., 1998). CRH also
increased vascular permeability in
human skin, an effect dependent on
CRH-R1 and mast cells (Crompton
et al., 2003).
The level of stress in these patients
was not quantitated with any validated
instrument and it is, therefore, prema-
ture to try to make any correlations
between our findings and any level of
stress in these patients.
Mast cells are involved not only in
allergic reactions, but also in innate
immunity (Galli et al., 2005) and
inflammation (Theoharides and Co-
chrane, 2004). Mast cells are juxta-
posed to nerve endings during
hair follicle formation (Roloff et al.,
1998) and are located close to CRH-
positive nerve endings (Rozniecki et al.,
1999), suggesting that they are involved
in a ‘‘brain–skin’’ connection (Paus
et al., 2006), as targets of CRH and
related peptides (Theoharides et al.,
2004).
The present findings suggest that
CRH and CRH-R1 may participate in
the pathogenesis of psoriasis, especially
when worsened by stress.
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Figure 1. Skin CRH recetor expression and serum CRH levels in psoriasis. (a) CRH-R gene expression in
skin samples from psoriasis patients (n¼ 13) and controls (n¼4) by quantitative real-time–PCR was
obtained from non-exposed skin (back and gluteal). Samples of unaffected skin of psoriasis patients were
obtained from sites at least 15 cm away from lesional areas. All biopsies were immediately placed in
RNAlater solution (Ambion Inc., Austin, TX) and stored at 201C. Relative quantities of mRNA expression
were normalized using 18S as an internal control. TaqMan was performed with cDNA reverse transcribed
from 100 ng RNA from each sample. (b) Serum CRH levels in psoriasis patients (n¼ 8) and controls
(n¼4) measured using an ELISA kit (R&D Systems, Mineapolis, MN) (*Po0.05). Statistics: the efficiency
of the quantitative PCR machine was shown to be 1.8 and the equation we use is 1/(1.8^Ct). This value
was calculated for each condition and results are expressed as a ratio of mRNA expression for CRH-R to
18S. Results are presented as mean7SD and were compared with controls (set at 1) using one-way
analysis of variance on ranks followed by Dunn’s correction for multiple comparisons. Significance is
denoted by (psor¼ psoriasis) *Po0.05.
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TO THE EDITOR
Transglutaminases (TGs) are a family of
nine Ca2þ -dependent enzymes (types
1–7, band 4.2, factor XIII) that catalyze
cross-linking reaction resulting in the
formation of an Ne-(g-glutamyl lysine)
isopeptide bound between their sub-
strates (Griffin et al., 2002; Lorand and
Graham, 2003; Esposito and Caputo,
2005). TG-modified proteins are more
resistant to proteolytic degradation andAbbreviations: TG, Transglutaminase; hTG3, human TG3
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